Sector
1063 stories · page 44 of 54
The over-allotment option saw an additional 4,200,000 units purchased for additional gross proceeds of $5.25 million
CEO Steven McAuley told shareholders that the company "has never looked better"
AME-1 is the company's proprietary extract from Amanita mushrooms, also known as Fly Agaric, which it says can be useful for preparations for human health
Two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of a SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and an animal research pharmacokinetic study (VIRAL-A20-2)
Below we take a closer look at Shield Therapeutics...
The firm is the only Canadian public company licensed to work with the full range of psychedelics and to produce and extract psilocybin from mushrooms
Hear from executives at Aion Therapeutic, Lobe Sciences and Silo Pharma at Proactive's psychedelic-themed virtual showcase event on Tuesday February 23
Hear executives from Silo Pharma and Lobe Sciences at Proactive's psychedelic-themed virtual showcase event on Tuesday, February 23
The company said the gross proceeds from the offering will be used to fully fund the pre-clinical trials of the company's Amanita Muscaria extract, AME-1 and to continue its scientific research of AME-1 and its potential benefits for people
Studies have shown that administering ketanserin, a 5-HT2A receptor antagonist, before administering LSD almost completely prevents the psychedelic drug’s acute effects
The new goal is to offer the first dose to another 2mln people by April while administering the booster to the 15mln inoculated so far
The company said it intends to use the net proceeds for Phase 3 clinical costs for Bucillamine for coronavirus (COVID-19), Phase 1 clinical costs for Psilocybin for methamphetamine use disorder study, and other Psychedelic formulation de
The New York City-based company has several projects in various stages from planning to ongoing clinical trials with a strong focus on legendary LSD
"In working with Sport-Orthèse, we're signalling our dedication to our European clientele and furthering our goal for continued success on the continent," said Adam Cegielski, Binovi founder and CEO
The acquisition expands Numinus' presence into Quebec, building on its Vancouver office with two established locations and extensive virtual services as well as insights garnered from a decade of successful clinic management.
He will lead the R&D initiatives of N,N-Dimethyltryptamine (DMT) for mental health, neurological, and inflammatory disorders
Not just that, the Canada-listed business has planted flags in Germany and the Netherlands
Chairman Roger McIntyre said vice-chair Bill Wilkerson has retired from the board while former senior television executive Olga Cwiek will be joining
The six-item patient-administered RMS differentiates the more cyclical bipolar I disorder compared to MDD in patients with depressive symptoms
The new Canadian Rapid Treatment Centre of Excellence (CRTCE) provides ketamine treatment for adults with depression